Virtual reality brain training from home may slow Alzheimer's — study investigates
NCT ID NCT07722169
First seen Jul 23, 2026 · Last updated Aug 04, 2026 · Updated 3 times
Summary
This trial tests whether home-based virtual reality cognitive exercises, done on a tablet, can help slow mental decline in people with mild-to-moderate Alzheimer's disease. Some participants will also have online sessions with a neuropsychologist. The study aims to find a practical, validated way to deliver cognitive training remotely, potentially easing the burden on caregivers and the healthcare system.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- home-based virtual reality cognitive training using VRRS tablets, with or without online cognitive telerehabilitation sessions supervised by a neuropsychologist
- What this could lead to
- If effective, this approach could offer a validated, scalable way to slow cognitive decline in Alzheimer's disease while reducing caregiver burden and healthcare costs.
- What could go wrong
- This is a small, early-stage study (48 participants) testing a non-drug intervention, so results may not generalize. The benefit may be modest, and adherence to home training could be challenging.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 48 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Oct 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 90 years
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion criteria for patients with Alzheimer's disease (AD): * Age between 50 and 90 years. * Diagnosis of Alzheimer's disease according to established diagnostic criteria. * Mini-Mental State Examination (MMSE) score between 18 and 24. * Stable pharmacological treatment for at least 3 months before enrolment. * Ability and willingness to provide written informed consent. Inclusion criteria for caregivers: * Age ≥18 years. * Availability to assist the patient throughout the study. * Ability and willingness to provide written informed consent. Exclusion criteria for patients with Alzheimer's disease (AD): * Refusal or inability to provide written informed consent. * History of psychiatric disorders. * Significant cerebrovascular disease. * Severe visual or hearing impairment that could interfere with study procedures. * Psychosis. * Major depressive disorder. * Alcohol or substance abuse. * Use of psychotropic medications that may interfere with neuropsychological assessment or study treatment. * Concurrent participation in another interventional pharmacological clinical trial. * Any contraindication to undergoing EEG recording. Exclusion criteria for caregivers: * Refusal or inability to provide written informed consent. * History of psychiatric disorders. * Major depressive disorder. * Alcohol or substance abuse. * Use of psychotropic medications that may interfere with neuropsychological assessment.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Alzheimer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.